Patents Assigned to Synvista Therapeutics, Inc.
  • Publication number: 20090124674
    Abstract: Provided, among other things, is a method of treating or ameliorating or preventing an indication of the invention in an animal, including a human comprising administering an effective amount of a compound of the formula I:
    Type: Application
    Filed: January 9, 2009
    Publication date: May 14, 2009
    Applicant: Synvista Therapeutics, Inc.
    Inventors: John Egan, Sara Vasan, Martin Gall, Sheng Ding Fang, Dilip Wagle, Parmod Wagle
  • Publication number: 20090124673
    Abstract: Provided, among other things, is a method of treating or ameliorating or preventing an indication of the invention in an animal, including a human comprising administering an effective amount of a compound of the formula I:
    Type: Application
    Filed: January 9, 2009
    Publication date: May 14, 2009
    Applicant: Synvista Therapeutics , Inc.
    Inventors: John Egan, Sara Vasan, Martin Gall, Sheng Ding Fang, Dilip Wagle, Pramod Wagle
  • Publication number: 20090088461
    Abstract: The present invention relates to a method of treating or preventing cardiac disorders, myocardial inflammation or myocardial oxidative stress associated with a high fat diet or in a patient subjected to a high fat diet using the thiazolium compounds and compositions of the invention. The present invention also relates to a method of ameliorating weight gain, myocardial AGE accumulation associated, mitochondrial superoxide production, RAGE expression or PPAR? expression with a high fat diet or in a patient subjected to a high fat diet using the thiazolium compounds and compositions of the invention.
    Type: Application
    Filed: September 26, 2008
    Publication date: April 2, 2009
    Applicant: Synvista Therapeutics, Inc.
    Inventors: Merlin Thomas, Josephine Forbes, Christos Tikellis
  • Patent number: 7511036
    Abstract: Provided are compounds of the formula (and pharmaceutically acceptable salts thereof): wherein: R is hydrogen, methyl, hydroxymethyl or ?-hydroxyethyl; R1 and R2 are independently selected from hydrogen, C1-C6 alkyl, C1-C6 hydroxyalkyl, C3-C8 cycloalkyl, C1-C6 alkenyl, C1-C6 alkynyl, amino, monoalkylamino, dialkylaminoalkyl, and pyrrolidin-1-ylalkyl; and Y is selected from the group consisting of C1-C6 alkyl, substituted and unsubstituted aryl; with the provisos that: (a) if Y is aryl, then at least one of R1 and R2 is other than hydrogen, and (b) if R2 is hydrogen R1 is other than methyl. Also provided are pharmaceutical compositions containing the compounds, and methods for the preparation of the compounds. The compounds are useful, among other things, as prodrugs which can be converted under acidic conditions to thiazolium agents. The compounds can be administered to mammals, including humans, for treatment of various indications.
    Type: Grant
    Filed: March 27, 2006
    Date of Patent: March 31, 2009
    Assignee: Synvista Therapeutics, Inc.
    Inventors: Emily Reinhard, Elliot Katten
  • Patent number: 7432254
    Abstract: Provided is a method of treating or ameliorating or preventing glaucoma, decreasing intraocular pressure or improving or amemliorting ocular accommodation in an animal, including a human comprising administering an intraocular pressure decreasing or accommodation improving amount of a compound of the formula I:
    Type: Grant
    Filed: December 31, 2001
    Date of Patent: October 7, 2008
    Assignee: Synvista Therapeutics, Inc.
    Inventors: John J. Egan, Dilip Wagle, Sara Vasan, Martin Gall, Stanley Bell, Edmond Joseph LaVoie